Source: Hypertension. Unidade: FM
Subjects: HIPERTENSÃO, MONITORIZAÇÃO AMBULATORIAL DA PRESSÃO ARTERIAL, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KRIEGER, Eduardo M. et al. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension, v. 71, n. 4, p. 681-690, 2018Tradução . . Disponível em: https://doi.org/10.1161/HYPERTENSIONAHA.117.10662. Acesso em: 25 abr. 2026.APA
Krieger, E. M., Drager, L. F., Lotufo, P. A., & Krieger, J. E. (2018). Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension, 71( 4), 681-690. doi:10.1161/HYPERTENSIONAHA.117.10662NLM
Krieger EM, Drager LF, Lotufo PA, Krieger JE. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment) [Internet]. Hypertension. 2018 ; 71( 4): 681-690.[citado 2026 abr. 25 ] Available from: https://doi.org/10.1161/HYPERTENSIONAHA.117.10662Vancouver
Krieger EM, Drager LF, Lotufo PA, Krieger JE. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment) [Internet]. Hypertension. 2018 ; 71( 4): 681-690.[citado 2026 abr. 25 ] Available from: https://doi.org/10.1161/HYPERTENSIONAHA.117.10662
